Modification of the detrimental effect of TNF-α on human endothelial progenitor cells by fasudil and Y27632

Journal of Biochemical and Molecular Toxicology

Volumn 24, Issue 6, 2010, Pages 351-360

  Balestrieri, Maria Luisa ^a   Giovane, Alfonso ^a   Milone, Lara ^a   Felice, Francesca ^a   Fiorito, Carmela ^b   Crudele, Valeria ^a   Esposito, Annaclaudia ^a   Rossiello, Raffaele ^a   Minucci, Pellegrino Biagio ^a   Farzati, Bartolomeo ^a   Servillo, Luigi ^a   Napoli, Claudio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Endothelial progenitor cells; Fasudil; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIN RELATED PROTEIN; ADENYLATE CYCLASE; FASUDIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 78650503592     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20345     Document Type: Article

References (46)

1. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008;78:413-421.
2. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.
3. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
4. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009;13:87-102.
5. Shantsila F, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007;49:741-752.
6. Napoli C, Maione C, Schiano C, Fiorito C, Ignarro LJ. Bone marrow cell-mediated cardiovascular repair: potential of combined therapies. Trends Mol Med 2007;13:278-286.
7. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002;360:427-435.
8. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-1232.
9. Liguori A, Fiorito C, Balestrieri ML, Crimi E, Bruzzese G, Williams-Ignarro S, D'Amora M, Sommese L, Grimaldi V, Minucci PB, Giovane A, Farzati B, Ignarro LJ, Napoli C. Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease. Eur J Haematol 2008;80:258-264.
10. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002;106:2781-2786.
11. Cubbon RM, Rajwani A, Wheatcroft SB. The impact of insulin resistance on endothelial function, progenitor cells and repair. Diab Vasc Dis Res 2007;4:103-111.
12. Xiao Q, Kiechl S, Patel S, Oberhollenzer F, Weger S, Mayr A, Metzler B, Reindl M, Hu Y, Willeit J, Xu Q. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis-results from a large population-based study. PLoS ONE 2007;2:e975.
13. Paul JD, Powell TM, Thompson M, Benjamin M, Rodrigo M, Carlow A, Annavajjhala V, Shiva S, Dejam A, Gladwin MT, McCoy JP, Zalos G, Press B, Murphy M, Hill JM, Csako G, Waclawiw MA, Cannon RO, III. Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation. J Cardiopulm Rehabil Prev 2007;27:65-73.
14. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adle K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
15. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rössig L, Spyridopoulos I, Zeiher AM, Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003;92:1049-1055.
16. Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, Asai J, Tsutsumi Y, Sekiguchi H, Silver M, Wecker A, Bord E, Zhu Y, Kishore R, Losordo DW. Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 2006;114:2261-2270.
17. Masuda H, Kalka C, Takahashi T, Yoshida M, Wada M, Kobori M, Itoh R, Iwaguro H, Eguchi M, Iwami Y, Tanaka R, Nakagawa Y, Sugimoto A, Ninomiya S, Hayashi S, Kato S, Asahara T. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res 2007;101:598-606.
18. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007;192:67-74.
19. Balestrieri ML, Schiano C, Felice F, Casamassimi A, Balestrieri A, Milone L, Servillo L, Napoli C. Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. J Biochem 2008;143:179-186.
20. Balestrieri ML, Fiorito C, Crimi E, Felice F, Schiano C, Milone L, Casamassimi A, Giovane A, Grimaldi V, Del Giudice V, Minucci PB, Mancini FP, Servillo L, D'Armiento FP, Farzati B, Napoli C. Effect of red wine antioxidants and minor polyphenolic constituents on endothelial progenitor cells after physical training in mice. Int J Cardiol 2008;126:295-297.
21. de Nigris F, Balestrieri ML, Ignarro S-W, D'Armiento FP, Lerman LO, Byrns R, Crimi E, Palagiano A, Sica V, Ignarro LJ, Napoli C. Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hind limb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. J Cardiov Pharmacol 2007;50:424-433.
22. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005;25:1767-1775.
23. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005;183:1-16.
24. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.
25. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 2002;22:243-248.
26. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006;99:1426-1432.
27. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57-62.
28. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004;95:579-586.
29. Shirai H, Autieri M, Eguchi S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 2007;16:111-115.
30. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 2009;16:1355-1365.
31. Chan CK, Mak JC, Man RY, Vanhoutte PM. Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta. J Pharmacol Exp Ther 2009;329:820-826.
32. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008;20:242-248.
33. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002;40:751-761.
34. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales-Ballejo H, Thadani U. Fasudil Study Group. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-1811.
35. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002;105:1545-1547.
36. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003;41:15-19.
37. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005;111:2741-2747.
38. Casamassimi A, Balestrieri ML, Fiorito C, Schiano C, Maione C, Rossiello R, Grimaldi V, Del Giudice V, Balestrieri C, Farzati B, Sica V, Napoli C. Comparison between total endothelial progenitor cell isolation versus enriched Cd133 + culture. J Biochem 2007;141:503-511.
39. Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, Rossig L, Corbaz A, Chvatchko Y, Zeiher AM, Dimmeler S. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005;111:1184-1191.
40. Balestrieri ML, Rienzo M, Felice F, Rossiello R, Grimaldi V, Milone L, Casamassimi A, Servillo L, Farzati B, Giovane A, Napoli C. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim Biophys Acta 2008;1784:936-945.
41. Fiorito C, Balestrieri ML, Crimi E, Giovane A, Grimaldi V, Minucci PB, Servillo L, D'Armiento FP, Farzati B, Napoli C. Effect of l-arginine on circulating endothelial progenitor cells and VEGF after moderate physical training in mice. Int J Cardiol 2008;126:421-423.
42. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007;50:17-24.
43. Rodriguez OC, Schaefer AW, Mandato CA, Forscher P, Bement WM, Waterman-Storerl CM. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat Cell Biol 2003;5:599-609.
44. Gorovoy M, Niu J, Bernard O, Profirovic J, Minshall R, Neamu R, Voyno-Yasenetskaya, T. LIM kinase 1 coordinates microtubule stability and actin polymerization in human endothelial cells. J Biol Chem 2005;280:26533-26542.
45. Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J. TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic. Tempol Am J Physiol Heart Circ Physiol 2007;293:H2726-H2737.
46. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 2004;104:3591-3597.